NO20076363L - Fremgangsmate for fremstilling av vaksiner - Google Patents

Fremgangsmate for fremstilling av vaksiner

Info

Publication number
NO20076363L
NO20076363L NO20076363A NO20076363A NO20076363L NO 20076363 L NO20076363 L NO 20076363L NO 20076363 A NO20076363 A NO 20076363A NO 20076363 A NO20076363 A NO 20076363A NO 20076363 L NO20076363 L NO 20076363L
Authority
NO
Norway
Prior art keywords
saccharide
protein
vaccines
procedures
preparation
Prior art date
Application number
NO20076363A
Other languages
English (en)
Other versions
NO345305B1 (no
Inventor
Pierre Duvivier
Ralph Leon Biemans
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36716943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20076363(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0513069.5A external-priority patent/GB0513069D0/en
Priority claimed from GBGB0513071.1A external-priority patent/GB0513071D0/en
Priority claimed from GB0515556A external-priority patent/GB0515556D0/en
Priority claimed from GB0524204A external-priority patent/GB0524204D0/en
Priority claimed from GB0526040A external-priority patent/GB0526040D0/en
Priority claimed from GB0526041A external-priority patent/GB0526041D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20076363L publication Critical patent/NO20076363L/no
Publication of NO345305B1 publication Critical patent/NO345305B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Surgical Instruments (AREA)

Abstract

Foreliggende søknad beskriver en forbedret metode for utføring av sakkarid-protein konjugeringsreaksjoner ved anvendelse av karbodiimid kondenseringskjemi. Avhengig av typen av sakkarid eller proteinbærer involvert, kan kvaliteten av konjugatet forbedres ved tilsetning av én av reaksjonskomponentene langsomt til reaksjonsblandingen. Immunogene preparater er videre tilveiebragt, omfattende sakkarid-protein-konjugater fremstilt ved metodene beskrevet
NO20076363A 2005-06-27 2007-12-12 Metode for konjugering av et sakkarid til en proteinbærer ved anvendelse av karbodiimid kondenseringskjemi samt sakkarid-protein bærerkonjugat NO345305B1 (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB0513069.5A GB0513069D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GBGB0513071.1A GB0513071D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GB0515556A GB0515556D0 (en) 2005-07-28 2005-07-28 Immunogenic composition
GB0524204A GB0524204D0 (en) 2005-11-28 2005-11-28 Immunogenic composition
GB0526040A GB0526040D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
GB0526041A GB0526041D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
PCT/EP2006/006270 WO2007000343A2 (en) 2005-06-27 2006-06-23 Process for manufacturing vaccines

Publications (2)

Publication Number Publication Date
NO20076363L true NO20076363L (no) 2008-03-26
NO345305B1 NO345305B1 (no) 2020-12-07

Family

ID=36716943

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20076343A NO345422B1 (no) 2005-06-27 2006-06-23 Immunogent preparat, vaksine omfattende immunogent preparat, fremgangsmåte for fremstilling av vaksinen og anvendelse av immunogent preparat for behandling eller forebygging av sykdom.
NO20076302A NO344452B1 (no) 2005-06-27 2007-12-07 Immunogent preparat, vaksine, vaksinesett samt fremgangsmåte for fremstilling av vaksinen.
NO20076350A NO342815B1 (no) 2005-06-27 2007-12-11 Immunogent preparat og fremgangsmåte for fremstilling av en vaksine.
NO20076363A NO345305B1 (no) 2005-06-27 2007-12-12 Metode for konjugering av et sakkarid til en proteinbærer ved anvendelse av karbodiimid kondenseringskjemi samt sakkarid-protein bærerkonjugat

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NO20076343A NO345422B1 (no) 2005-06-27 2006-06-23 Immunogent preparat, vaksine omfattende immunogent preparat, fremgangsmåte for fremstilling av vaksinen og anvendelse av immunogent preparat for behandling eller forebygging av sykdom.
NO20076302A NO344452B1 (no) 2005-06-27 2007-12-07 Immunogent preparat, vaksine, vaksinesett samt fremgangsmåte for fremstilling av vaksinen.
NO20076350A NO342815B1 (no) 2005-06-27 2007-12-11 Immunogent preparat og fremgangsmåte for fremstilling av en vaksine.

Country Status (36)

Country Link
US (13) US9789179B2 (no)
EP (11) EP1896065B2 (no)
JP (9) JP2008543907A (no)
KR (7) KR101351870B1 (no)
CN (3) CN102526723B (no)
AP (1) AP2436A (no)
AR (3) AR056397A1 (no)
AT (3) ATE516816T1 (no)
AU (7) AU2006263963B2 (no)
BE (1) BE2012C042I2 (no)
BR (5) BRPI0612655B1 (no)
CA (5) CA2612980C (no)
CY (5) CY1109996T1 (no)
DE (1) DE602006013313D1 (no)
DK (7) DK1896063T3 (no)
EA (4) EA013374B1 (no)
ES (9) ES2377075T5 (no)
FR (1) FR22C1008I2 (no)
HR (4) HRP20110567T4 (no)
HU (7) HUE031380T2 (no)
IL (8) IL187924A (no)
LT (2) LT2351578T (no)
LU (2) LU92085I2 (no)
MA (4) MA29602B1 (no)
MX (5) MX2007016405A (no)
MY (3) MY147490A (no)
NL (2) NL300549I2 (no)
NO (4) NO345422B1 (no)
NZ (6) NZ564607A (no)
PE (6) PE20070163A1 (no)
PL (8) PL1896061T3 (no)
PT (8) PT1896065E (no)
SI (8) SI2283857T1 (no)
TW (5) TWI407970B (no)
UA (2) UA95238C2 (no)
WO (6) WO2007000327A1 (no)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1296715T4 (en) * 2000-06-29 2016-03-07 Smithkline Beecham Biolog Multivalent vaccine composition.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
ES2461350T3 (es) 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
LT2351578T (lt) * 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
EP2308504A3 (en) 2005-09-01 2011-11-30 Novartis Vaccines and Diagnostics GmbH Multiple vaccines including serogroup C meningococcus
AU2012261764B2 (en) * 2005-09-01 2016-09-08 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup C meningococcus
BRPI0620460B8 (pt) 2005-12-22 2021-05-25 Glaxosmithkline Biologicals Sa uso de composição imunogênica para bebês, e, processo para produzir uma vacina
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
ES2383209T3 (es) 2006-03-22 2012-06-19 Novartis Ag Regímenes para la inmunización con conjugados meningococicos
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EA015964B1 (ru) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
BRPI0813644B8 (pt) * 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
MX2011002267A (es) * 2008-08-28 2011-03-30 Glaxosmithkline Biolog Sa Vacuna.
CN102264444B (zh) 2008-10-27 2015-08-05 诺华股份有限公司 纯化方法
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
US20120064103A1 (en) 2009-03-24 2012-03-15 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
PL2411048T3 (pl) 2009-03-24 2020-11-16 Glaxosmithkline Biologicals Sa Adjuwantowe meningokokowe białko wiążące czynnik h
JP5593626B2 (ja) * 2009-03-31 2014-09-24 凸版印刷株式会社 計量スプーン
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2010125480A1 (en) * 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
SA114350400B1 (ar) * 2009-06-22 2016-05-26 ويث ال ال سي تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
PL2493498T3 (pl) * 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
JP2013112653A (ja) * 2011-11-30 2013-06-10 Jnc Corp 新規重合体およびその製造方法
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
AU2011384634A1 (en) 2011-12-29 2014-06-19 Novartis Ag Adjuvanted combinations of meningococcal factor H binding proteins
MX354103B (es) * 2012-01-30 2018-02-13 Serum Inst India Ltd Composicion inmunogenica.
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
CN102569723A (zh) * 2012-02-13 2012-07-11 华为技术有限公司 锂离子电池正极材料及其制备方法、正极及锂离子电池
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
JP2015509963A (ja) 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP2892553A1 (en) 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
ITMI20121597A1 (it) * 2012-09-25 2014-03-26 Beta Pharma S A Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico
CA2885625A1 (en) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Nonlinear saccharide conjugates
US9987344B2 (en) 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
US20150320852A1 (en) 2012-12-18 2015-11-12 Glaxosmithkline Biologicals Sa Conjugates for protecting against diphtheria and/or tetanus
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
SI2976101T1 (sl) * 2013-03-18 2021-01-29 Glaxosmithkline Biologicals S.A. Metoda zdravljenja
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
IN2014DE02450A (no) 2013-09-25 2015-06-26 Suzuki Motor Corp
RU2535122C1 (ru) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения холерогена-анатоксина
US12616744B2 (en) 2014-01-21 2026-05-05 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PT3096785T (pt) * 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
EP3131576B1 (en) 2014-04-17 2021-06-30 Medizinische Hochschule Hannover Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
US20170333546A1 (en) * 2015-12-08 2017-11-23 Jl Medical Corporation Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein
RU2758090C2 (ru) * 2016-03-15 2021-10-26 Мсд Уэлком Траст Хиллеман Лабораторис Пвт. Лтд. Новые конъюгаты полисахарида с белком и способ их получения
RS65362B1 (sr) 2016-09-02 2024-04-30 Sanofi Pasteur Inc Vakcina protiv neisseria meningitidis
WO2018042015A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
EP3530285B1 (en) * 2016-10-20 2023-08-09 KM Biologics Co., Ltd. METHOD FOR PRODUCING HIB CONJUGATE VACCINE USING PRP WITH
LOWERED MOLECULAR WEIGHT
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US20200353064A1 (en) * 2018-01-29 2020-11-12 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112022008761A2 (pt) 2019-11-22 2022-07-26 Glaxosmithkline Biologicals Sa Dosagem e administração de uma vacina de glicoconjugado de sacarídeo
CN116847879A (zh) 2020-11-13 2023-10-03 葛兰素史密丝克莱恩生物有限公司 细菌蛋白载体和缀合方法
RU2770877C1 (ru) * 2021-04-08 2022-04-22 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ получения антигенной конъюгированной субстанции гемофильного типа b микроба для создания вакцинных препаратов
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
WO2025021710A1 (en) 2023-07-21 2025-01-30 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB513069A (en) 1937-04-24 1939-10-03 Linde Air Prod Co Improvements in method of and apparatus for the treatment of metallic bodies by oxidising gas
GB505518A (en) † 1938-02-03 1939-05-12 Daniel Morgan Skeins Improvements in or relating to envelopes
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4123520A (en) * 1977-08-01 1978-10-31 Merck & Co., Inc. Method for preparing high molecular weight meningococcal Group C vaccine
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4235994A (en) * 1978-06-26 1980-11-25 Merck & Co., Inc. High molecular weight meningococcal group C vaccine and method for preparation thereof
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
DE3040825A1 (de) * 1980-10-30 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach Neues tridekapeptid, verfahren zu seiner herstellung und verwendung
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
HU193083B (en) * 1984-02-22 1987-08-28 Sandoz Ag Process for preparing diazepinoindole derivatives further pharmaceutical compositions containing such compounds
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3526940A1 (de) 1985-07-27 1987-02-12 Siegfried Fricker Anker zum einbetonieren in schwere lasten
IL78929A0 (en) 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US5180815A (en) * 1988-04-13 1993-01-19 Fuji Photo Film Co., Ltd. Modified protein for carrying hapten
US5115924A (en) 1988-05-31 1992-05-26 Beatrice Konig-Haug Shelf system
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
ATE121947T1 (de) 1989-12-14 1995-05-15 Ca Nat Research Council Verbessertes meningokokkale polysaccharidkonjugatvakzin.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
GB2264352A (en) 1992-01-31 1993-08-25 Richards Eng Ltd Incineration apparatus
AU685047B2 (en) 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
ATE178907T1 (de) 1992-05-06 1999-04-15 Harvard College Rezeptorbindende region des diphtherietoxius
DE69319728T2 (de) 1992-05-23 1999-02-04 Smithkline Beecham Biologicals S.A., Rixensart Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2126616T3 (es) 1992-10-27 1999-04-01 American Cyanamid Co Vacuna pediatrica combinada, con una inmunogenecidad aumentada de cada componente de la vacuna.
AU5951894A (en) 1992-12-14 1994-07-04 Western Atlas International, Inc. Removable piston bore liner for hydraulically actuated seismic vibrator
ES2210262T3 (es) 1993-09-22 2004-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas.
US5849301A (en) 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
AU712981B2 (en) 1995-03-22 1999-11-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
NZ311000A (en) 1995-06-07 1999-04-29 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein
IL122588A (en) 1995-06-23 2001-12-23 Smithkline Beecham Biolog A combination vaccine containing a polysaccharide conjugated antigen attached to a phosphate aluminum and one or more additional antibodies
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
EP1271490B1 (en) 1996-10-23 2011-12-21 Panasonic Corporation Optical disk
CA2271720A1 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
WO1998026799A1 (en) 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugate vaccine for salmonella paratyphi a
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
AU4707097A (en) 1997-09-15 1999-04-05 Pasteur Merieux Serums Et Vaccins Multivalent vaccines
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
WO1999055715A2 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
AU1626199A (en) † 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
DE69940439D1 (de) 1998-12-21 2009-04-02 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
EP2286792A1 (en) 1999-02-26 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Microemulsions with an adsorbent surface, comprising a microdroplet emulsion
JP2002539273A (ja) * 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
ES2343304T3 (es) * 1999-06-25 2010-07-28 Wyeth Holdings Corporation Produccion de la forma lipidada de las lipoproteinas asociadas a peptidoglicano de bacterias gram-negativas.
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
DK1233784T3 (da) 1999-12-02 2008-09-01 Novartis Vaccines & Diagnostic Præparater og fremgangsmåder til stabilisering af biologiske molekyler efter lyofilisering
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
DK1296715T4 (en) 2000-06-29 2016-03-07 Smithkline Beecham Biolog Multivalent vaccine composition.
KR20030024811A (ko) * 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
ATE439372T1 (de) * 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic Nukleinsäuren und proteine von gruppen a und b- streptokokken
PT2332581E (pt) * 2001-01-23 2015-10-16 Sanofi Pasteur Inc Vacina meningocócica tri- ou tetravalente de conjugados de polissacárido e crm-197
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
US6615062B2 (en) 2001-05-31 2003-09-02 Infraredx, Inc. Referencing optical catheters
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CU23031A1 (es) 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
MXPA04008890A (es) 2002-03-15 2005-10-18 Wyeth Corp Mutantes de la proteina p4 de haemophilus influenzae no tipicable con actividad enzimatica reducida.
DK1777236T3 (en) * 2002-03-26 2017-02-27 Glaxosmithkline Biologicals Sa MODIFIED SUCCARIDES WHICH IMPROVED WATER STABILITY FOR USE AS A MEDICINE
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
CN1816350B (zh) 2002-05-14 2010-11-10 莱顿大学 带有几丁聚糖佐剂和/或脑膜炎抗原的粘膜疫苗
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
US20040096461A1 (en) 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
CA2493124C (en) 2002-08-02 2014-04-29 Glaxosmithkline Biologicals S.A. Vaccine
GB0220199D0 (en) 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CN1809380B (zh) * 2002-10-11 2010-05-12 启龙有限公司 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
CN1401328A (zh) * 2002-10-18 2003-03-12 北京绿竹生物技术有限责任公司 流行性脑脊髓膜炎多糖－蛋白结合疫苗
MXPA05004528A (es) 2002-11-01 2005-07-26 Glaxosmithkline Biolog Sa Composicion inmunogenica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN1168501C (zh) 2002-12-27 2004-09-29 北京绿竹生物技术有限责任公司 一种多糖-蛋白结合疫苗
ES2461350T3 (es) * 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
PT1601689E (pt) * 2003-03-13 2008-01-04 Glaxosmithkline Biolog Sa Processo de purificação para citolisina bacteriana
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
JP2006528936A (ja) * 2003-05-07 2006-12-28 アヴェンティス パストゥール インコーポレイテッド 多価髄膜炎菌誘導体化多糖−タンパク質複合体およびワクチン
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2530434A1 (en) 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
KR101034055B1 (ko) 2003-07-18 2011-05-12 엘지이노텍 주식회사 발광 다이오드 및 그 제조방법
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
CA2844154C (en) * 2003-08-06 2016-12-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US6995363B2 (en) * 2003-08-21 2006-02-07 Applera Corporation Reduction of matrix interference for MALDI mass spectrometry analysis
ATE474595T1 (de) * 2003-10-02 2010-08-15 Glaxosmithkline Biolog Sa B. pertussis antigene und ihre verwendung bei der vakzinierung
NZ546430A (en) * 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
JP5173194B2 (ja) 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
JP5393978B2 (ja) 2004-04-05 2014-01-22 ゾエティス・ピー・エルエルシー マイクロ流動化された水中油型乳剤及びワクチン組成物
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US9402915B2 (en) 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP2298340B1 (en) * 2004-09-22 2014-04-16 GlaxoSmithKline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP2425853A1 (en) * 2005-04-08 2012-03-07 Wyeth LLC Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
BRPI0611447A2 (pt) 2005-05-06 2010-09-08 Stockholm University imunógenos para vacinas contra meningite a
LT2351578T (lt) * 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
CN1709505B (zh) 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
EP2308504A3 (en) 2005-09-01 2011-11-30 Novartis Vaccines and Diagnostics GmbH Multiple vaccines including serogroup C meningococcus
ES2407683T3 (es) * 2005-09-05 2013-06-13 Glaxosmithkline Biologicals S.A. Ensayo bactericida del suero para antisuero específico de N. Meningitidis
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
BRPI0620460B8 (pt) 2005-12-22 2021-05-25 Glaxosmithkline Biologicals Sa uso de composição imunogênica para bebês, e, processo para produzir uma vacina
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
WO2007071786A2 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
CN101405028B (zh) * 2006-03-17 2015-08-19 美国政府健康及人类服务部 制备复合的多价免疫原性结合物的方法
MY148405A (en) * 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
CN101479293A (zh) 2006-06-29 2009-07-08 诺华有限公司 脑膜炎奈瑟球菌多肽
US7491517B2 (en) * 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
WO2008011120A2 (en) 2006-07-21 2008-01-24 The Regents Of The University Of California Human endogenous retrovirus polypeptide compositions and methods of use thereof
EA015964B1 (ru) * 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
WO2008111374A1 (ja) * 2007-03-14 2008-09-18 Konica Minolta Business Technologies, Inc. 情報埋め込み方法、そのプログラムおよび情報埋め込み装置
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
JP5637848B2 (ja) * 2007-06-04 2014-12-10 ノバルティス アーゲー 髄膜炎ワクチンの製剤化
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
MX2011002267A (es) * 2008-08-28 2011-03-30 Glaxosmithkline Biolog Sa Vacuna.
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
US8259461B2 (en) * 2008-11-25 2012-09-04 Micron Technology, Inc. Apparatus for bypassing faulty connections
EP2493510B1 (en) * 2009-09-30 2020-07-08 GlaxoSmithKline Biologicals SA Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
BR112012022800A2 (pt) * 2010-03-11 2018-05-15 Glaxosmithkline Biologicals Sa composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica
JP5144836B2 (ja) * 2010-06-11 2013-02-13 パナソニック株式会社 語音聴取の評価システム、その方法およびそのプログラム
WO2013068949A1 (en) * 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
MX354103B (es) * 2012-01-30 2018-02-13 Serum Inst India Ltd Composicion inmunogenica.
RU2014151567A (ru) * 2012-05-22 2016-07-10 Новартис Аг Конъюгат менингококка серогруппы х
WO2014001328A1 (en) 2012-06-25 2014-01-03 Nadiro A/S A lifeboat deployment unit
HRP20230359T1 (hr) * 2012-12-05 2023-06-09 Glaxosmithkline Biologicals Sa Imunogeni pripravak
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
US10245310B2 (en) * 2014-08-05 2019-04-02 Glaxosmithkline Biologicals Sa Carrier molecule for antigens
TWI715617B (zh) * 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
RS65362B1 (sr) * 2016-09-02 2024-04-30 Sanofi Pasteur Inc Vakcina protiv neisseria meningitidis
US11951165B2 (en) * 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10183070B2 (en) * 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112020000999A2 (pt) * 2017-07-18 2020-07-14 Serum Institute Of India Pvt Ltd. composição imunogênica tendo estabilidade aperfeiçoada, imunogenicidade melhorada e reatogenicidade reduzida e processo para a sua preparação

Also Published As

Publication number Publication date
IL213718A (en) 2013-07-31
JP5297800B2 (ja) 2013-09-25
TW201414490A (zh) 2014-04-16
WO2007000343A3 (en) 2007-05-31
EA012506B1 (ru) 2009-10-30
JP5769688B2 (ja) 2015-08-26
BRPI0612670B8 (pt) 2021-05-25
IL222346A (en) 2015-07-30
EP1896066A2 (en) 2008-03-12
CY1112698T1 (el) 2016-02-10
ES2377075T3 (es) 2012-03-22
FR22C1008I2 (fr) 2024-01-19
MY147490A (en) 2012-12-14
CY1109996T1 (el) 2014-09-10
EA012214B1 (ru) 2009-08-28
US20130171188A1 (en) 2013-07-04
LUC00247I2 (no) 2024-10-04
EA200702577A1 (ru) 2008-06-30
AU2010203115A1 (en) 2010-08-12
EP1896063A1 (en) 2008-03-12
BRPI0612656A2 (pt) 2010-11-30
ES2901378T3 (es) 2022-03-22
WO2007000327A1 (en) 2007-01-04
CN103083657A (zh) 2013-05-08
HK1114011A1 (en) 2008-10-24
EP1896061A2 (en) 2008-03-12
US10166287B2 (en) 2019-01-01
KR101359953B1 (ko) 2014-02-21
PT1896063E (pt) 2012-02-13
EP2878307B1 (en) 2019-07-24
LU92085I9 (no) 2019-01-04
DK2351578T3 (en) 2017-04-24
WO2007000341A3 (en) 2007-05-31
US20090136541A1 (en) 2009-05-28
US20080199490A1 (en) 2008-08-21
PL2351578T3 (pl) 2017-07-31
CN102218138A (zh) 2011-10-19
JP5731737B2 (ja) 2015-06-10
EP1896064A2 (en) 2008-03-12
CA2612957A1 (en) 2007-01-04
EA013374B1 (ru) 2010-04-30
LT2351578T (lt) 2017-04-10
NZ590204A (en) 2012-02-24
WO2007000314A2 (en) 2007-01-04
PL1896063T3 (pl) 2012-04-30
SI1896063T1 (sl) 2012-03-30
SI2283857T1 (sl) 2019-11-29
EP1896065A2 (en) 2008-03-12
DK1896065T4 (da) 2014-10-20
PE20070123A1 (es) 2007-02-08
MA29602B1 (fr) 2008-07-01
HRP20120102T1 (hr) 2012-02-29
CY1111827T1 (el) 2015-10-07
HRP20170457T1 (hr) 2017-05-19
HK1206587A1 (en) 2016-01-15
IL188046A0 (en) 2008-03-20
EP2201961A1 (en) 2010-06-30
NO20076302L (no) 2008-03-26
PL2878307T3 (pl) 2020-01-31
WO2007000343A2 (en) 2007-01-04
MX2007016403A (es) 2008-03-07
PT3009146T (pt) 2021-11-30
MX2007016237A (es) 2008-03-07
KR20130122810A (ko) 2013-11-08
HUE056842T2 (hu) 2022-03-28
US20100215686A1 (en) 2010-08-26
US20090252759A1 (en) 2009-10-08
CN103083657B (zh) 2016-06-08
EP1896063B2 (en) 2016-03-02
EA012528B1 (ru) 2009-10-30
BRPI0612656A8 (pt) 2018-01-23
CN102526723B (zh) 2017-07-07
KR101321056B1 (ko) 2013-10-30
PL2283857T3 (pl) 2020-02-28
BE2012C042I2 (no) 2021-07-19
KR101351873B1 (ko) 2014-02-17
CA2611960A1 (en) 2007-01-04
IL214657A0 (en) 2011-09-27
PT1896062E (pt) 2010-05-17
AU2006263963A1 (en) 2007-01-04
AU2006263944A1 (en) 2007-01-04
AR056397A1 (es) 2007-10-10
US20080193476A1 (en) 2008-08-14
ATE516816T1 (de) 2011-08-15
ES2741529T3 (es) 2020-02-11
KR101408113B1 (ko) 2014-06-16
PE20070163A1 (es) 2007-03-01
IL213795A (en) 2013-05-30
NO20076350L (no) 2008-03-26
IL188072A0 (en) 2008-03-20
HRP20110567T4 (xx) 2015-01-16
SI3009146T1 (sl) 2022-02-28
US20180064806A1 (en) 2018-03-08
AU2006263963B2 (en) 2010-05-13
WO2007000322A1 (en) 2007-01-04
EP1896063B1 (en) 2011-12-14
US8846049B2 (en) 2014-09-30
HUE045482T2 (hu) 2019-12-30
EP1896066B1 (en) 2021-10-27
MX2007016405A (es) 2008-03-07
AP2436A (en) 2012-08-31
NL301151I2 (nl) 2025-12-15
BRPI0612654B1 (pt) 2021-05-04
HK1116414A1 (en) 2008-12-24
MX2007016402A (es) 2008-03-07
EP2283857B1 (en) 2019-07-24
MX2007016236A (es) 2008-03-07
JP2008543908A (ja) 2008-12-04
NZ564607A (en) 2011-06-30
CY2012027I2 (el) 2015-10-07
ES2898451T3 (es) 2022-03-07
TWI537001B (zh) 2016-06-11
JP5718960B2 (ja) 2015-05-13
US9789179B2 (en) 2017-10-17
MY148110A (en) 2013-02-28
EP1896065B1 (en) 2011-07-20
BRPI0612654B8 (pt) 2021-05-25
WO2007000342A3 (en) 2007-05-31
PE20110096A1 (es) 2011-03-07
TWI477283B (zh) 2015-03-21
KR20080018216A (ko) 2008-02-27
PT2351578T (pt) 2017-04-07
EP3009146A1 (en) 2016-04-20
NO345422B1 (no) 2021-01-25
BRPI0612670B1 (pt) 2020-04-28
ATE536884T1 (de) 2011-12-15
HRP20100211T1 (hr) 2010-05-31
CA2612963C (en) 2016-10-18
NO342815B1 (no) 2018-08-13
NO345305B1 (no) 2020-12-07
KR101532068B1 (ko) 2015-06-29
US10245317B2 (en) 2019-04-02
ES2747025T3 (es) 2020-03-09
JP2015134829A (ja) 2015-07-27
LTC1896065I2 (lt) 2025-06-10
PE20110072A1 (es) 2011-02-04
PL3009146T3 (pl) 2022-02-07
NL300549I2 (no) 2017-01-03
US20090041802A1 (en) 2009-02-12
TWI422386B (zh) 2014-01-11
EP2283857A1 (en) 2011-02-16
BRPI0612654A2 (pt) 2012-10-02
CA2611964A1 (en) 2007-01-04
EP2351578B1 (en) 2017-01-18
HUS2200002I1 (hu) 2022-12-28
PT2283857T (pt) 2019-10-24
ATE462444T1 (de) 2010-04-15
MA29993B1 (fr) 2008-12-01
SI1896061T1 (sl) 2019-10-30
EP1896066B8 (en) 2022-01-19
PL1896065T5 (pl) 2014-12-31
BRPI0612669B8 (pt) 2021-05-25
ES2662651T3 (es) 2018-04-09
HUS000497I2 (hu) 2021-03-29
LTPA2012019I1 (lt) 2012-11-26
UA95237C2 (uk) 2011-07-25
PE20070499A1 (es) 2007-05-21
DK2878307T3 (da) 2019-10-07
NO344452B1 (no) 2019-12-09
IL187924A0 (en) 2008-03-20
US20200000911A1 (en) 2020-01-02
AP2007004274A0 (en) 2007-12-31
AR053935A1 (es) 2007-05-23
WO2007000342A2 (en) 2007-01-04
SI1896062T1 (sl) 2010-07-30
IL188046A (en) 2012-03-29
BRPI0612669B1 (pt) 2019-08-13
HUE046905T2 (hu) 2020-03-30
KR20080018226A (ko) 2008-02-27
EP3009146B1 (en) 2021-10-20
PL1896062T3 (pl) 2010-08-31
ES2377075T5 (es) 2016-04-29
CN102526723A (zh) 2012-07-04
US11241495B2 (en) 2022-02-08
AU2006263965B2 (en) 2012-09-13
BRPI0612655B1 (pt) 2021-06-15
CA2612957C (en) 2016-07-19
AU2010212417A1 (en) 2010-09-09
AU2006263936B2 (en) 2010-05-20
PL1896061T3 (pl) 2020-02-28
LU92085I2 (fr) 2012-12-19
SI2878307T1 (sl) 2019-11-29
US20190298822A1 (en) 2019-10-03
JP2008543905A (ja) 2008-12-04
AU2010203115C1 (en) 2013-05-02
BRPI0612655A2 (pt) 2010-11-30
NZ564605A (en) 2011-01-28
IL188072A (en) 2017-07-31
JP5965512B2 (ja) 2016-08-03
JP2008543909A (ja) 2008-12-04
DK1896063T3 (da) 2012-03-19
HUS1200023I1 (hu) 2021-03-29
SI1896065T1 (sl) 2011-10-28
CA2611960C (en) 2015-05-05
BRPI0612655A8 (pt) 2018-01-30
MA29603B1 (fr) 2008-07-01
JP2013018798A (ja) 2013-01-31
JP2013107913A (ja) 2013-06-06
SI1896065T2 (sl) 2014-12-31
CA2612980C (en) 2019-01-15
US9931397B2 (en) 2018-04-03
US9358279B2 (en) 2016-06-07
JP2013209395A (ja) 2013-10-10
BRPI0612670A2 (pt) 2010-11-30
AU2010203115B2 (en) 2012-03-15
KR20130086087A (ko) 2013-07-30
BRPI0612656B1 (pt) 2021-09-08
CY2012027I1 (el) 2015-10-07
CA2611964C (en) 2016-11-08
US8883163B2 (en) 2014-11-11
JP2008543904A (ja) 2008-12-04
MY147783A (en) 2013-01-31
AU2006263964B2 (en) 2010-05-20
NZ564371A (en) 2010-05-28
JP2008543907A (ja) 2008-12-04
AU2006263944B2 (en) 2012-03-01
EP2201961B1 (en) 2018-01-24
IL213718A0 (en) 2011-07-31
PL1896065T3 (pl) 2011-12-30
EP2878307A1 (en) 2015-06-03
US9486515B2 (en) 2016-11-08
KR20080025184A (ko) 2008-03-19
MA29569B1 (fr) 2008-06-02
ES2340711T3 (es) 2010-06-08
NZ564606A (en) 2010-10-29
DK1896065T3 (da) 2011-08-29
FR22C1008I1 (fr) 2022-04-29
US8431136B2 (en) 2013-04-30
US8398983B2 (en) 2013-03-19
EA200702574A1 (ru) 2008-06-30
KR101351870B1 (ko) 2014-02-17
US8329184B2 (en) 2012-12-11
AU2006263936A1 (en) 2007-01-04
ES2621780T3 (es) 2017-07-05
EP1896062A1 (en) 2008-03-12
ES2750243T3 (es) 2020-03-25
DK2283857T3 (da) 2019-10-28
WO2007000314A3 (en) 2007-05-31
CA2612963A1 (en) 2007-01-04
IL188045A0 (en) 2008-03-20
AU2006263965A1 (en) 2007-01-04
EP2351578A1 (en) 2011-08-03
NZ564370A (en) 2011-10-28
CY1118646T1 (el) 2017-07-12
DK1896062T3 (da) 2010-06-28
HUE047211T2 (hu) 2020-04-28
IL187924A (en) 2011-11-30
IL213795A0 (en) 2011-07-31
PT1896065E (pt) 2011-08-31
TW201336507A (zh) 2013-09-16
US20130004532A1 (en) 2013-01-03
KR20080024222A (ko) 2008-03-17
NO20076343L (no) 2008-03-25
JP5037503B2 (ja) 2012-09-26
KR20080030577A (ko) 2008-04-04
WO2007000341A2 (en) 2007-01-04
HK1116413A1 (en) 2008-12-24
HRP20110567T1 (en) 2011-09-30
EA200702576A1 (ru) 2008-06-30
US20150044253A1 (en) 2015-02-12
TWI407970B (zh) 2013-09-11
TW200730187A (en) 2007-08-16
EP1896061B1 (en) 2019-06-12
PT1896061T (pt) 2019-08-01
PE20142165A1 (es) 2015-01-09
US20170065714A1 (en) 2017-03-09
EA200702575A1 (ru) 2008-06-30
JP5280199B2 (ja) 2013-09-04
CA2612980A1 (en) 2007-01-04
DE602006013313D1 (de) 2010-05-12
PT2878307T (pt) 2019-10-24
EP1896065B2 (en) 2014-09-03
AR056396A1 (es) 2007-10-10
BRPI0612669A2 (pt) 2010-11-30
TW200738259A (en) 2007-10-16
DK1896061T3 (da) 2019-08-26
HUE031380T2 (en) 2017-07-28
AU2006263964A1 (en) 2007-01-04
UA95238C2 (uk) 2011-07-25
SI2351578T1 (sl) 2017-05-31
WO2007000342A8 (en) 2008-07-10
EP1896062B1 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
WO2007000343A3 (en) Process for manufacturing vaccines
WO2008081014A3 (en) Process for manufacturing vaccines
Detz et al. Enantioselective Copper‐Catalysed Propargylic Substitution: Synthetic Scope Study and Application in Formal Total Syntheses of (+)‐Anisomycin and (−)‐Cytoxazone
CY1119416T1 (el) Αντισωματα εναντι των τοξινων toy clostridium difficile (κλωστηριδιο το δυσκολο) και χρησεις εξ' αυτων
WO2006031560A3 (en) Process for concentration of antibodies and therapeutic products thereof
CR8765A (es) Preparacion de pregabalina y compuestos relacionados
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
WO2006005074A3 (en) Novel hot start nucleic acid amplification
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
NO20080590L (no) Humane, monoklonale antistoffer mot programmert dodsligand (PD-L1)
PH12015501848A1 (en) Binding agents
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
MX348432B (es) Epitopes.
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
NO20083053L (no) Humane monoklonale antistoffer mot O8E
TW200732346A (en) Chimeric hepatitis C virus antigens for eliciting an immune response
WO2008139206A3 (en) Optical imaging agents
MX2010001723A (es) Formulaciones de anticuerpos y moleculas de fusion-fc usando policationes.
DE602004031368D1 (de) Universelle vervielfältigung von fragmentierter rns
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
BRPI0412916A (pt) formulações liofilizadas de cci-779
WO2008046232A8 (en) Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation
Thedy et al. Exploring Metallaphotoredox Catalysis: A Synergistic Approach to Biomolecule Functionalization
WO2006015370A3 (en) Site specific system for generating diversity protein sequences